Blaxhult A, Lidman K
Infektionskliniken, Danderyds Sjukhus.
Nord Med. 1998 Nov;113(9):290-2, 296.
The treatment of HIV infection in the industrialised countries has undergone manifest changes during the past decade. Since the advent of zidovudine in 1987, the first agent capable of delaying disease progression, several other nucleoside analogues have been introduced, though in retrospect the effect of these drugs can now be seen to have been moderate. With the introduction of proteinase inhibitors, more effective control of infection became possible, and the combination of a proteinase inhibitor with two nucleoside analogues yielded a triple-drug treatment capable of halting progression for a large proportion of patients. Thus, during recent years the disease course has changed in character from successive deterioration of the immune defence system to a condition where most patients can live virtually normal lives in many respects. For some patients, however, the new drugs have been associated with side effects, and our knowledge of the long-term effects is still insufficient.
在过去十年间，工业化国家对艾滋病毒感染的治疗已发生显著变化。自1987年齐多夫定问世以来，这是第一种能够延缓疾病进展的药物，此后又引入了其他几种核苷类似物，不过现在回顾起来，这些药物的效果只能说是中等。随着蛋白酶抑制剂的引入，对感染进行更有效控制成为可能，蛋白酶抑制剂与两种核苷类似物的联合使用产生了一种三联药物疗法，能够使很大一部分患者停止病情进展。因此，近年来，疾病进程的性质已从免疫防御系统的持续恶化转变为大多数患者在许多方面实际上可以过上正常生活的状况。然而，对一些患者来说，这些新药会带来副作用，而且我们对其长期影响的了解仍然不足。
